- Home
- GXAI vs PULM Comparison
GXAI vs PULM Comparison
Compare GXAI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- PULM
- Stock Information
- Founded
- GXAI 2021
- PULM 2003
- Country
- GXAI United States
- PULM United States
- Employees
- GXAI N/A
- PULM N/A
- Industry
- GXAI
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- PULM Health Care
- Exchange
- GXAI Nasdaq
- PULM Nasdaq
- Market Cap
- GXAI 19.7M
- PULM 20.5M
- IPO Year
- GXAI 2023
- PULM N/A
- Fundamental
- Price
- GXAI $1.72
- PULM $5.00
- Analyst Decision
- GXAI
- PULM
- Analyst Count
- GXAI 0
- PULM 0
- Target Price
- GXAI N/A
- PULM N/A
- AVG Volume (30 Days)
- GXAI 15.2M
- PULM 9.7K
- Earning Date
- GXAI 11-13-2025
- PULM 11-07-2025
- Dividend Yield
- GXAI N/A
- PULM N/A
- EPS Growth
- GXAI N/A
- PULM N/A
- EPS
- GXAI N/A
- PULM N/A
- Revenue
- GXAI $198,711.00
- PULM $369,000.00
- Revenue This Year
- GXAI N/A
- PULM N/A
- Revenue Next Year
- GXAI N/A
- PULM $134.88
- P/E Ratio
- GXAI N/A
- PULM N/A
- Revenue Growth
- GXAI 72158.55
- PULM N/A
- 52 Week Low
- GXAI $1.00
- PULM $1.78
- 52 Week High
- GXAI $7.50
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- GXAI 54.22
- PULM 49.10
- Support Level
- GXAI $1.41
- PULM $4.70
- Resistance Level
- GXAI $1.85
- PULM $4.87
- Average True Range (ATR)
- GXAI 0.20
- PULM 0.12
- MACD
- GXAI -0.03
- PULM 0.08
- Stochastic Oscillator
- GXAI 32.98
- PULM 70.00
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).